BTIG has lowered its price target for Humacyte (HUMA) but continues to hold a bullish view on the company's long-term opportunities.

Humacyte has secured a $1.48 million commitment for the purchase of its Symvess product in Saudi Arabia, marking a significant business development.

Humacyte reported its Q4 GAAP EPS of -$0.13, which was in-line with expectations, but its revenue of $0.47 million missed estimates, with further details emerging from its earnings call.

A preview of Super League's financial performance for the fourth quarter of 2025 has been released.